JP2016514117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514117A5 JP2016514117A5 JP2015562180A JP2015562180A JP2016514117A5 JP 2016514117 A5 JP2016514117 A5 JP 2016514117A5 JP 2015562180 A JP2015562180 A JP 2015562180A JP 2015562180 A JP2015562180 A JP 2015562180A JP 2016514117 A5 JP2016514117 A5 JP 2016514117A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- piperazin
- hydroxy
- tert
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 1-hydroxycyclopropyl Chemical group 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 15
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 14
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 10
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- ZKQGJMPEAJQJIT-UHFFFAOYSA-N n-[4-[2-[4-(2-tert-butyl-6-cyclobutylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound N=1C(C(C)(C)C)=NC(C2CCC2)=CC=1N(CC1)CCN1CCC(CC1)CCC1NC(=O)C1CCC(O)CC1 ZKQGJMPEAJQJIT-UHFFFAOYSA-N 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 125000005475 oxolanyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006420 1-fluorocyclopropyl group Chemical group [H]C1([H])C([H])([H])C1(F)* 0.000 claims 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- UMVJFUPSFWNGLR-BIQTVELOSA-N C1[C@@H](OC)C[C@@H]1C(=O)NC1CCC(CCN2CCN(CC2)C=2N=C(N=C(C=2)C(C)C)C(C)(C)C)CC1 Chemical compound C1[C@@H](OC)C[C@@H]1C(=O)NC1CCC(CCN2CCN(CC2)C=2N=C(N=C(C=2)C(C)C)C(C)(C)C)CC1 UMVJFUPSFWNGLR-BIQTVELOSA-N 0.000 claims 1
- MFDCOFBYJDNAHX-CRIZEEMZSA-N C1[C@@H](OC)C[C@@H]1C(=O)NC1CCC(CCN2C[C@H](C)N(CC2)C=2N=C(N=C(C=2)C(C)C)C(C)(C)C)CC1 Chemical compound C1[C@@H](OC)C[C@@H]1C(=O)NC1CCC(CCN2C[C@H](C)N(CC2)C=2N=C(N=C(C=2)C(C)C)C(C)(C)C)CC1 MFDCOFBYJDNAHX-CRIZEEMZSA-N 0.000 claims 1
- XIPDODHKFSTWGQ-UNCSOSLYSA-N CC(C)(C)C1=NC(C(C)(C)C)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(C)(C)C)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 XIPDODHKFSTWGQ-UNCSOSLYSA-N 0.000 claims 1
- XIPDODHKFSTWGQ-YROJFRDXSA-N CC(C)(C)C1=NC(C(C)(C)C)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(C)(C)C)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 XIPDODHKFSTWGQ-YROJFRDXSA-N 0.000 claims 1
- JNJLNDBHIQMMPS-NMICXILDSA-N CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 JNJLNDBHIQMMPS-NMICXILDSA-N 0.000 claims 1
- HFUDTZKQQFGRIB-UNCSOSLYSA-N CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 HFUDTZKQQFGRIB-UNCSOSLYSA-N 0.000 claims 1
- HFUDTZKQQFGRIB-YROJFRDXSA-N CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 HFUDTZKQQFGRIB-YROJFRDXSA-N 0.000 claims 1
- WPXYHLDUFCEGNH-KHDOTFDESA-N CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3CC(C3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3CC(C3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 WPXYHLDUFCEGNH-KHDOTFDESA-N 0.000 claims 1
- GIAFISQEJLFPRO-ONXIHUBWSA-N CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3CCC(CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3CCC(CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 GIAFISQEJLFPRO-ONXIHUBWSA-N 0.000 claims 1
- XNYXVAQMIGIMNF-KHDOTFDESA-N CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3CCC(CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3CCC(CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)C)=N1 XNYXVAQMIGIMNF-KHDOTFDESA-N 0.000 claims 1
- RWBKBXNQRHXCFO-CASZSKKGSA-N CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3C[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2[C@H](CN(CCC3C[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 RWBKBXNQRHXCFO-CASZSKKGSA-N 0.000 claims 1
- PWTMJTJEUYXRGM-STUVXCIXSA-N CC(C)(C)C1=NC(C(F)F)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(F)F)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 PWTMJTJEUYXRGM-STUVXCIXSA-N 0.000 claims 1
- PWTMJTJEUYXRGM-CHDDOINTSA-N CC(C)(C)C1=NC(C(F)F)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(C(F)F)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 PWTMJTJEUYXRGM-CHDDOINTSA-N 0.000 claims 1
- NJQSWCFXZVWOMT-OMHPJYQNSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@H](CC3)OC)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@H](CC3)OC)CC2)=N1 NJQSWCFXZVWOMT-OMHPJYQNSA-N 0.000 claims 1
- YWYFBRTZORKIBD-QQHARNDCSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 YWYFBRTZORKIBD-QQHARNDCSA-N 0.000 claims 1
- NJQSWCFXZVWOMT-NJSSPPMUSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@H](CC3)OC)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@H](CC3)OC)CC2)=N1 NJQSWCFXZVWOMT-NJSSPPMUSA-N 0.000 claims 1
- YWYFBRTZORKIBD-JENPDSIZSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 YWYFBRTZORKIBD-JENPDSIZSA-N 0.000 claims 1
- GIYCGBQBBYXNLG-QNNDVPKGSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3C[C@@H](C3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3C[C@@H](C3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 GIYCGBQBBYXNLG-QNNDVPKGSA-N 0.000 claims 1
- GIYCGBQBBYXNLG-DVAIQPOTSA-N CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3C[C@H](C3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CC[C@@H]3C[C@H](C3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 GIYCGBQBBYXNLG-DVAIQPOTSA-N 0.000 claims 1
- UDRZDLDHIYMICU-HUNBZTQFSA-N CC(C)(C)C1=NC(CCOC)=CC(N2[C@@H](CN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2[C@@H](CN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 UDRZDLDHIYMICU-HUNBZTQFSA-N 0.000 claims 1
- UDRZDLDHIYMICU-CXTGUETESA-N CC(C)(C)C1=NC(CCOC)=CC(N2[C@@H](CN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2[C@@H](CN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 UDRZDLDHIYMICU-CXTGUETESA-N 0.000 claims 1
- UDRZDLDHIYMICU-WOKGGPCBSA-N CC(C)(C)C1=NC(CCOC)=CC(N2[C@H](CN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2[C@H](CN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 UDRZDLDHIYMICU-WOKGGPCBSA-N 0.000 claims 1
- UDRZDLDHIYMICU-CPHHOOCTSA-N CC(C)(C)C1=NC(CCOC)=CC(N2[C@H](CN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2[C@H](CN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)C)=N1 UDRZDLDHIYMICU-CPHHOOCTSA-N 0.000 claims 1
- JMUVTNVAYVZJCW-WHMPLDHSSA-N CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 JMUVTNVAYVZJCW-WHMPLDHSSA-N 0.000 claims 1
- KAKCCJBQFXRMBC-JPAKECIRSA-N CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 KAKCCJBQFXRMBC-JPAKECIRSA-N 0.000 claims 1
- JMUVTNVAYVZJCW-AKMOFFSESA-N CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=N1 JMUVTNVAYVZJCW-AKMOFFSESA-N 0.000 claims 1
- KAKCCJBQFXRMBC-CTOYOCAESA-N CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 Chemical compound CC(C)(C)C1=NC(COC)=CC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3C[C@@H](O)C3)CC2)=N1 KAKCCJBQFXRMBC-CTOYOCAESA-N 0.000 claims 1
- GIAFISQEJLFPRO-LROMGURASA-N CC(C)c1cc(nc(n1)C(C)(C)C)N1CCN(CC[C@H]2CC[C@@H](CC2)NC(=O)[C@H]2CC[C@H](O)CC2)C[C@@H]1C Chemical compound CC(C)c1cc(nc(n1)C(C)(C)C)N1CCN(CC[C@H]2CC[C@@H](CC2)NC(=O)[C@H]2CC[C@H](O)CC2)C[C@@H]1C GIAFISQEJLFPRO-LROMGURASA-N 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- GYHDKJBMDCWPJZ-STUVXCIXSA-N FC(F)(F)C1=NC(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=C1 Chemical compound FC(F)(F)C1=NC(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=C1 GYHDKJBMDCWPJZ-STUVXCIXSA-N 0.000 claims 1
- GYHDKJBMDCWPJZ-CHDDOINTSA-N FC(F)(F)C1=NC(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=C1 Chemical compound FC(F)(F)C1=NC(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=C1 GYHDKJBMDCWPJZ-CHDDOINTSA-N 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- ZKQGJMPEAJQJIT-GHYQBBAPSA-N N([C@@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1CC[C@H](O)CC1 Chemical compound N([C@@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1CC[C@H](O)CC1 ZKQGJMPEAJQJIT-GHYQBBAPSA-N 0.000 claims 1
- SQBFSJJWETYMEO-VGOHXSHPSA-N N([C@@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 Chemical compound N([C@@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 SQBFSJJWETYMEO-VGOHXSHPSA-N 0.000 claims 1
- FOPADUAPJQWDQL-PWEACROJSA-N N([C@@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCCC1)C(=O)[C@H]1CC[C@H](O)CC1 Chemical compound N([C@@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCCC1)C(=O)[C@H]1CC[C@H](O)CC1 FOPADUAPJQWDQL-PWEACROJSA-N 0.000 claims 1
- UNBJBRUJGOJLIT-VGOHXSHPSA-N N([C@@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1CC[C@H](O)CC1 Chemical compound N([C@@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1CC[C@H](O)CC1 UNBJBRUJGOJLIT-VGOHXSHPSA-N 0.000 claims 1
- FRZXOHYLOHTWIQ-ZPSYDCNQSA-N N([C@@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 Chemical compound N([C@@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 FRZXOHYLOHTWIQ-ZPSYDCNQSA-N 0.000 claims 1
- SQBFSJJWETYMEO-MLRKGSHFSA-N N([C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 Chemical compound N([C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 SQBFSJJWETYMEO-MLRKGSHFSA-N 0.000 claims 1
- FOPADUAPJQWDQL-WHLKPCPKSA-N N([C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCCC1)C(=O)[C@H]1CC[C@H](O)CC1 Chemical compound N([C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCCC1)C(=O)[C@H]1CC[C@H](O)CC1 FOPADUAPJQWDQL-WHLKPCPKSA-N 0.000 claims 1
- UNBJBRUJGOJLIT-MLRKGSHFSA-N N([C@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1CC[C@H](O)CC1 Chemical compound N([C@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1CC[C@H](O)CC1 UNBJBRUJGOJLIT-MLRKGSHFSA-N 0.000 claims 1
- FRZXOHYLOHTWIQ-XHPGVBHPSA-N N([C@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 Chemical compound N([C@H]1C[C@@H](C1)CCN1CCN(CC1)C=1C=C(N=C(N=1)C(C)(C)C)C1CCC1)C(=O)[C@H]1C[C@H](O)C1 FRZXOHYLOHTWIQ-XHPGVBHPSA-N 0.000 claims 1
- MKGUUJLFVLEKNI-UNCSOSLYSA-N N=1C(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=CC=1C1(C)CC1 Chemical compound N=1C(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=CC=1C1(C)CC1 MKGUUJLFVLEKNI-UNCSOSLYSA-N 0.000 claims 1
- MKGUUJLFVLEKNI-YROJFRDXSA-N N=1C(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=CC=1C1(C)CC1 Chemical compound N=1C(C(C)(C)C)=NC(N2CCN(CC[C@@H]3CC[C@H](CC3)NC(=O)[C@@H]3CC[C@@H](O)CC3)CC2)=CC=1C1(C)CC1 MKGUUJLFVLEKNI-YROJFRDXSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000008450 motivation Effects 0.000 claims 1
- FRZXOHYLOHTWIQ-UHFFFAOYSA-N n-[3-[2-[4-(2-tert-butyl-6-cyclobutylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclobutyl]-3-hydroxycyclobutane-1-carboxamide Chemical compound N=1C(C(C)(C)C)=NC(C2CCC2)=CC=1N(CC1)CCN1CCC(C1)CC1NC(=O)C1CC(O)C1 FRZXOHYLOHTWIQ-UHFFFAOYSA-N 0.000 claims 1
- UNBJBRUJGOJLIT-UHFFFAOYSA-N n-[3-[2-[4-(2-tert-butyl-6-cyclobutylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclobutyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound N=1C(C(C)(C)C)=NC(C2CCC2)=CC=1N(CC1)CCN1CCC(C1)CC1NC(=O)C1CCC(O)CC1 UNBJBRUJGOJLIT-UHFFFAOYSA-N 0.000 claims 1
- GIYCGBQBBYXNLG-UHFFFAOYSA-N n-[3-[2-[4-[2-tert-butyl-6-(2-methoxyethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclobutyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CCC3CC(C3)NC(=O)C3CCC(O)CC3)CC2)=N1 GIYCGBQBBYXNLG-UHFFFAOYSA-N 0.000 claims 1
- XIPDODHKFSTWGQ-UHFFFAOYSA-N n-[4-[2-[4-(2,6-ditert-butylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(C(C)(C)C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=N1 XIPDODHKFSTWGQ-UHFFFAOYSA-N 0.000 claims 1
- SQBFSJJWETYMEO-UHFFFAOYSA-N n-[4-[2-[4-(2-tert-butyl-6-cyclobutylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-3-hydroxycyclobutane-1-carboxamide Chemical compound N=1C(C(C)(C)C)=NC(C2CCC2)=CC=1N(CC1)CCN1CCC(CC1)CCC1NC(=O)C1CC(O)C1 SQBFSJJWETYMEO-UHFFFAOYSA-N 0.000 claims 1
- FOPADUAPJQWDQL-UHFFFAOYSA-N n-[4-[2-[4-(2-tert-butyl-6-cyclopentylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound N=1C(C(C)(C)C)=NC(C2CCCC2)=CC=1N(CC1)CCN1CCC(CC1)CCC1NC(=O)C1CCC(O)CC1 FOPADUAPJQWDQL-UHFFFAOYSA-N 0.000 claims 1
- HFUDTZKQQFGRIB-UHFFFAOYSA-N n-[4-[2-[4-(2-tert-butyl-6-propan-2-ylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(C(C)C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=N1 HFUDTZKQQFGRIB-UHFFFAOYSA-N 0.000 claims 1
- YWYFBRTZORKIBD-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(2-methoxyethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-3-hydroxycyclobutane-1-carboxamide Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CC(O)C3)CC2)=N1 YWYFBRTZORKIBD-UHFFFAOYSA-N 0.000 claims 1
- IDOMSJDEDQUAKX-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(2-methoxyethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=N1 IDOMSJDEDQUAKX-UHFFFAOYSA-N 0.000 claims 1
- NJQSWCFXZVWOMT-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(2-methoxyethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-4-methoxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(CCOC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(CC3)OC)CC2)=N1 NJQSWCFXZVWOMT-UHFFFAOYSA-N 0.000 claims 1
- PWTMJTJEUYXRGM-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(difluoromethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(C(F)F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=N1 PWTMJTJEUYXRGM-UHFFFAOYSA-N 0.000 claims 1
- KAKCCJBQFXRMBC-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(methoxymethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-3-hydroxycyclobutane-1-carboxamide Chemical compound CC(C)(C)C1=NC(COC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CC(O)C3)CC2)=N1 KAKCCJBQFXRMBC-UHFFFAOYSA-N 0.000 claims 1
- JMUVTNVAYVZJCW-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(methoxymethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound CC(C)(C)C1=NC(COC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=N1 JMUVTNVAYVZJCW-UHFFFAOYSA-N 0.000 claims 1
- GYHDKJBMDCWPJZ-UHFFFAOYSA-N n-[4-[2-[4-[2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]ethyl]cyclohexyl]-4-hydroxycyclohexane-1-carboxamide Chemical compound FC(F)(F)C1=NC(C(C)(C)C)=NC(N2CCN(CCC3CCC(CC3)NC(=O)C3CCC(O)CC3)CC2)=C1 GYHDKJBMDCWPJZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786869P | 2013-03-15 | 2013-03-15 | |
| US61/786,869 | 2013-03-15 | ||
| US201361918524P | 2013-12-19 | 2013-12-19 | |
| US61/918,524 | 2013-12-19 | ||
| PCT/EP2014/055062 WO2014140246A1 (en) | 2013-03-15 | 2014-03-14 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016514117A JP2016514117A (ja) | 2016-05-19 |
| JP2016514117A5 true JP2016514117A5 (enExample) | 2017-04-06 |
Family
ID=50280387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562180A Pending JP2016514117A (ja) | 2013-03-15 | 2014-03-14 | ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアシルアミノシクロアルキル化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9388148B2 (enExample) |
| EP (1) | EP2970146B1 (enExample) |
| JP (1) | JP2016514117A (enExample) |
| CN (1) | CN105339357A (enExample) |
| AU (1) | AU2014230215A1 (enExample) |
| BR (1) | BR112015021471A2 (enExample) |
| CA (1) | CA2902656A1 (enExample) |
| MX (1) | MX2015012184A (enExample) |
| TW (1) | TW201514154A (enExample) |
| UY (1) | UY35420A (enExample) |
| WO (1) | WO2014140246A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| AR095264A1 (es) * | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| US10870660B2 (en) | 2016-07-28 | 2020-12-22 | Shionogi & Co., Ltd. | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect |
| JP7250405B2 (ja) | 2018-01-26 | 2023-04-03 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
| KR20200112910A (ko) | 2018-01-26 | 2020-10-05 | 시오노기 앤드 컴파니, 리미티드 | 도파민 d3 수용체 길항 작용을 갖는 축환 화합물 |
| WO2020156312A1 (zh) * | 2019-01-30 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
| CN112239433B (zh) * | 2019-07-17 | 2024-05-14 | 北京盈科瑞创新药物研究有限公司 | 一种环己烷衍生物、制备方法及其应用 |
| EP4053110A4 (en) * | 2019-10-29 | 2023-12-06 | Shanghai Hansoh Biomedical Co., Ltd. | FOUR-MEMBED RING DERIVATIVE MODIFIER, METHOD FOR PRODUCING THEREOF AND ITS USE |
| TWI873212B (zh) * | 2019-10-29 | 2025-02-21 | 大陸商上海翰森生物醫藥科技有限公司 | 四員環類衍生物調節劑、其製備方法和應用 |
| CN113754580B (zh) | 2020-06-05 | 2023-04-25 | 上海中泽医药科技有限公司 | 一种吡啶吗啉类化合物、其制备方法及其应用 |
| EP4332093A4 (en) * | 2021-04-28 | 2025-04-30 | Shanghai Hansoh Biomedical Co., Ltd. | Salt with polycyclic piperazine derivative, crystalline form thereof, production process therefor and use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10311065A1 (de) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
| JP2004359689A (ja) | 2003-06-05 | 2004-12-24 | Abbott Gmbh & Co Kg | ドーパミンｄ３受容体のモジュレーションに反応する障害の治療に適するトリアゾール化合物 |
| DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| DE102004027359A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
| JP4904267B2 (ja) | 2004-08-09 | 2012-03-28 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ドーパミンｄ３受容体の調節に応答する障害の治療に好適な４−ピペラジニル−ピリミジン化合物 |
| DE102004061593A1 (de) | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung |
| HUP0500170A3 (en) | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| EP1870405A1 (en) * | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| EP2173720A2 (en) | 2007-07-02 | 2010-04-14 | F. Hoffmann-Roche AG | 2-imidazolines having a good affinity to the trace amine associated receptors (taars) |
| PA8802101A1 (es) | 2007-11-02 | 2009-08-26 | Abbott Gmbh & Co Kg | Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 |
| US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| MX2011002628A (es) * | 2008-09-22 | 2011-04-05 | Hoffmann La Roche | Moduladores de los receptores d3 y 5-ht2a de piperazina. |
| EP2334644A1 (en) | 2008-09-23 | 2011-06-22 | F. Hoffmann-La Roche AG | Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors |
| US8586579B2 (en) | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8470828B2 (en) * | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
-
2014
- 2014-03-13 UY UY0001035420A patent/UY35420A/es not_active Application Discontinuation
- 2014-03-14 US US14/213,169 patent/US9388148B2/en active Active
- 2014-03-14 CA CA2902656A patent/CA2902656A1/en not_active Abandoned
- 2014-03-14 MX MX2015012184A patent/MX2015012184A/es unknown
- 2014-03-14 JP JP2015562180A patent/JP2016514117A/ja active Pending
- 2014-03-14 EP EP14710261.0A patent/EP2970146B1/en active Active
- 2014-03-14 AU AU2014230215A patent/AU2014230215A1/en not_active Abandoned
- 2014-03-14 WO PCT/EP2014/055062 patent/WO2014140246A1/en not_active Ceased
- 2014-03-14 CN CN201480026453.XA patent/CN105339357A/zh active Pending
- 2014-03-14 BR BR112015021471A patent/BR112015021471A2/pt not_active IP Right Cessation
- 2014-03-14 TW TW103109325A patent/TW201514154A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514117A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2012528178A5 (enExample) | ||
| JP2007518822A5 (enExample) | ||
| JP2013523733A5 (enExample) | ||
| PE20080360A1 (es) | Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3 | |
| BR112012015168A2 (pt) | "derivados de benzamida substituída". | |
| RU2015119241A (ru) | Соединения ациламиноциклоалкила, пригодные для лечения нарушений, которые отвечают на модуляцию рецептора допамина d3 | |
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| JP2016503785A5 (enExample) | ||
| JP2011517443A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2017509676A5 (enExample) | ||
| JP2014523420A5 (enExample) | ||
| JP2017505293A5 (enExample) | ||
| RU2018136888A (ru) | Нафтиридины в качестве антагонистов интегрина | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| JP2016504992A5 (enExample) | ||
| JP2012518634A5 (enExample) | ||
| RU2016132858A (ru) | Производные фторнафтила | |
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| JP2017502063A5 (enExample) | ||
| RU2015148927A (ru) | Производные изохинолина, стимулирующие нейрогенез | |
| JP2015502371A5 (enExample) | ||
| RU2013125338A (ru) | Производные триазола в качестве лигандов рецепторов гамк |